Multidisciplinary Oncologic Centre Antwerp (MOCA), Antwerp University Hospital, Edegem, Belgium.
Center for Oncological Research (CORE), University of Antwerp, Wilrijk, Belgium.
Breast J. 2020 May;26(5):995-999. doi: 10.1111/tbj.13696. Epub 2019 Dec 4.
Recently, the complex role of immune therapy has been the target of increased attention in breast cancer, particularly in triple-negative breast cancer (TNBC). Although TNBC is sensitive to chemotherapy, the recurrence and mortality rates are worse compared with the other breast cancer types. In addition, TNBC still lacks targeted treatment options. With the improved understanding of the immune system in TNBC, it is expected that new predictive and prognostic markers will be identified, and innovative treatment modalities will be developed. The aim of this review was to provide an overview of the effector cells in the TNBC's microenvironment and to highlight a novel approach to treat this kind of cancer. A computer-based literature research was carried out using PubMed, American Society of Clinical Oncology Annual Meeting (ASCO) and San Antonio Breast Cancer Symposium (SABCS). To date, studies have shown that tumor-infiltrating lymphocytes (TILs) and tumor-associated macrophages (TAMs) play a very important role in the TNBC's microenvironment. Tumor-infiltrating lymphocytes can even be considered as biomarkers to predict chemotherapy response in TNBC. Furthermore, TNBC was shown to have immune active subtypes, and therefore, the use of immunotherapy may be an attractive treatment approach. In this respect, several randomized studies have been designed or are currently ongoing to explore the combination of chemotherapy with immunotherapy in TNBC. Combination of chemo- and immunotherapy is likely to be beneficial in a subgroup of patients with TNBC.
最近，免疫疗法的复杂作用已成为乳腺癌研究的重点，尤其是在三阴性乳腺癌（TNBC）中。虽然 TNBC 对化疗敏感，但与其他乳腺癌类型相比，其复发率和死亡率更差。此外，TNBC 仍然缺乏靶向治疗选择。随着人们对 TNBC 中免疫系统认识的提高，预计将确定新的预测和预后标志物，并开发创新的治疗方式。本文旨在概述 TNBC 微环境中的效应细胞，并强调一种治疗这种癌症的新方法。我们通过计算机文献检索，利用 PubMed、美国临床肿瘤学会年会（ASCO）和圣安东尼奥乳腺癌研讨会（SABCS）进行了研究。迄今为止，研究表明，肿瘤浸润淋巴细胞（TILs）和肿瘤相关巨噬细胞（TAMs）在 TNBC 的微环境中起着非常重要的作用。肿瘤浸润淋巴细胞甚至可以被视为预测 TNBC 化疗反应的生物标志物。此外，TNBC 表现出免疫活性亚型，因此免疫疗法可能是一种有吸引力的治疗方法。在这方面，已经设计或正在进行几项随机研究，以探讨 TNBC 中化疗与免疫疗法的联合应用。化疗和免疫疗法的联合应用可能对 TNBC 患者的亚组有益。
